Загрузка...
Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study
Bendamustine + rituximab (BR) has demonstrated high response rates in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). However, progression-free survival (PFS) after BR is <18 months. This study was designed to determine if maintenance lenalidomid...
Сохранить в:
| Опубликовано в: : | Br J Haematol |
|---|---|
| Главные авторы: | , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5923897/ https://ncbi.nlm.nih.gov/pubmed/26913697 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13957 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|